I kliniske studier, fase III, udført på ALS patienter behandlet med rizulole, var de mest almindeligt rapporterede bivirkninger asteni, kvalme og abnorme leverfunktionstests.
In phase III clinical studies conducted in ALS patients treated with riluzole, the most commonly reported adverse reactions were asthenia, nausea and abnormal liver function tests.